‘Pharmony’ approach brings entire process under one roof
Almac Group (Audubon, PA) recently launched www.FindPharmony.com to give users a virtual view of the company’s new state-of-the-art headquarters, under construction to be one of the world’s largest integrated clinical supply and technology facilities.
Almac coined the term “pharmony” to describe the company’s approach, which combines planning, packaging, distribution, analysis and technology to make clinical trials more effective and efficient. Its strategy of bringing all the parts of the clinical trials process together under one roof is intended to create efficiencies, build collaboration and inspire innovation in drug development.
With the new North American headquarters, “For the first time, the people and processes necessary for successful integration of clinical supplies, testing and technology will be working together, hand-in-hand in real-time,” says Alan Armstrong, CEO of Almac.
FindPharmony.com will allow customers to watch the new building as it is being constructed, learn about community tours of headquarters and access job opportunities. Scheduled to officially open in Spring 2011 in Souderton, PA, close to Philadelphia, the 243,000-square-foot facility will house more than 750 employees.
Almac provides integrated development solutions to customers in the pharmaceutical and biotechnology sectors. Services include research and development, translational genomic services, API manufacturing, formulation and analytical development, clinical trial supply and technology services, and commercial-scale manufacturing and packaging.
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
How Industry Stakeholders View Medicare Advantage Expansion for Patients with Kidney Disease
July 7th 2025A qualitative study explores how MA plan leaders, kidney care managers, and dialysis providers perceive the benefits, risks, and marketing practices surrounding MA enrollment for patients with end-stage kidney disease.